Month: November 2024

Adhering to the core concept of "Integrated Cancer Prevention and Treatment, Winning through Integration," on November 14, 2024, a feast of knowledge on cancer prevention and treatment that brought together domestic and international medical elites, patient representatives, and leaders from all walks of life—The 2024 Chinese Congress on Holistic Integrative Oncology and The 40th Anniversary of China Anti-Cancer Association—grandly opened at the Xi'an International Conference Center.

The 2024 CACA Integrative Gastric Cancer Conference took place in Wuhan from October 18-19, 2024. Oncology Frontier invited Dr. Jie’er Ying, Chairman of the Chinese Anti-Cancer Association’s Gastric Cancer Integrative Rehabilitation Committee and Head of the Hepatobiliary and Gastric Oncology Department at Zhejiang Cancer Hospital, to discuss the current state and development of integrative rehabilitation for gastric cancer.

The 18th International Liver Cancer Association (ILCA) Annual Conference took place in Toronto, Canada, from October 17-19, 2024. During the conference, Prof. Richard S. Finn of the David Geffen School of Medicine at UCLA presented subgroup data from the real-world REFINE study, highlighting that patients with unresectable hepatocellular carcinoma (uHCC) who received transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in addition to regorafenib had better survival trends. Oncology Frontier invited Dr. Yunfei Yuan from the Sun Yat-sen University Cancer Center to discuss and provide insights on this study.

From October 25 to 27, 2024, the 9th Academic Symposium of the International Hepato-Pancreato-Biliary Association China Conference was held in Wuhan. The conference attracted more than 50 internationally renowned experts and scholars from over 20 countries including the United States, Germany, France, Russia, and Australia, as well as 21 academicians from the two academies and over 700 domestic experts in the field of hepato-pancreato-biliary. At this conference, Professor Eduard Jonas from the Groote Schuur Hospital, University of Cape Town, and President of the Europe-Africa Hepato-Pancreato-Biliary Association (E-AHPBA), delivered a wonderful report titled "Transitioning from guidelines to personalized medicine in the treatment of hepatocellular carcinoma - a global perspective." we invited Professor Eduard Jonas for an in-depth interview to share fascinating insights on the personalized treatment of liver cancer with colleagues in the field.

October 21-27, 2024, Wuhan, at the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (IHPBA), we interviewed Professor René Adam, the current President of the IHPBA and a famous surgeon at AP-HP Paul Brousse Hospital in Paris, France, to share his research explorations on the use of liver transplantation combined with chemotherapy for the treatment of colorectal cancer with liver metastases (CRLM).